Ruijin Hospital

Shanghai 200025

0 studies enrolling now · 7 studies all time

What they study most

Chronic Graft Versus Host Disease, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Indolent Lymphoma, Lung Cancer, MALT Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Non-Hodgkin's Lymphoma, Primary Mediastinal B-cell Lymphoma

Studies at this site

• A Long-term Extension Study of PCI-32765 (Ibrutinib) — Recruiting now
• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder — Running, not enrolling
• Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma — Running, not enrolling
• PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies — Status unconfirmed
• Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma — Completed
• Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission — Completed
• Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma — Completed